Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alpha Cognition Inc.ACOG · Entity 6339 | Director · Chief Executive Officer | January 09, 2026 | January 13, 2026 |
| Urovant Sciences Ltd.UROV · Entity 140739 | CCO/Urovant Sciences, Inc. | January 06, 2019 | January 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alpha Cognition Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 190,549 |
Reported balance
After 2026-01-09 transaction · row 1
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 190,549 · Balance 190,549 F1: Restricted stock units that vest on 1/3 on January 9, 2027, 1/3 on January 9, 2028 and 1/3 on January 9, 2029. |
| Common Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.56 · Expires 2036-01-13 | Direct | 177,576 |
Reported balance
After 2026-01-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-09 · Grant · Acquired 177,576 · Balance 177,576 F2: The options will vest 1/3 on January 9, 2027 and the remainder to vest in equal installments quarterly thereafter. |
| Performance Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $6.56 · Expires 2028-01-09 | Direct | 76,220 |
Reported balance
After 2026-01-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-09 · Grant · Acquired 76,220 · Balance 76,220 F3: Performance Share Units vesting at the end of the two-year period based on the Company?s closing stock price equaling or exceeding the applicable price level for at least twenty (20) trading days within any rolling thirty (30) consecutive trading-day period, as reported on the principal securities exchange on which the shares are listed, as follows: 19,550 common shares - $12.00 38,110 common shares - $18.00 57,165 common shares - $24.00 76,220 common shares - $28.00 |
| Common SharesSEC Table I · non-derivative | Indirectby The Michael and Sherri McFadden Family Trust | 14,142 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,142 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units that vest on 1/3 on January 9, 2027, 1/3 on January 9, 2028 and 1/3 on January 9, 2029.
F2: The options will vest 1/3 on January 9, 2027 and the remainder to vest in equal installments quarterly thereafter.
F3: Performance Share Units vesting at the end of the two-year period based on the Company?s closing stock price equaling or exceeding the applicable price level for at least twenty (20) trading days within any rolling thirty (30) consecutive trading-day period, as reported on the principal securities exchange on which the shares are listed, as follows: 19,550 common shares - $12.00 38,110 common shares - $18.00 57,165 common shares - $24.00 76,220 common shares - $28.00
Urovant Sciences Ltd.
Report date January 06, 2019 · Filed January 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2029-01-06 | Direct | 100,000 |
Reported balance
After 2019-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-06 · Grant · Acquired 100,000 · Balance 100,000 F1: 25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:20 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantPerformance Share Units · Derivative | 76,220 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000912282-26-000037 · form4.xml · derivative · entry 4 McFadden Michael E. · CIK 0001748333 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,220 Underlying: Common Shares · 76,220 shares Expires 2028-01-09 F3 · derivative.exercise_date: Performance Share Units vesting at the end of the two-year period based on the Company?s closing stock price equaling or exceeding the applicable price level for at least twenty (20) trading days within any rolling thirty (30) consecutive trading-day period, as reported on the principal securities exchange on which the shares are listed, as follows: 19,550 common shares - $12.00 38,110 common shares - $18.00 57,165 common shares - $24.00 76,220 common shares - $28.00 Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:20 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantCommon Share Options · Derivative | 177,576 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000912282-26-000037 · form4.xml · derivative · entry 3 McFadden Michael E. · CIK 0001748333 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,576 Underlying: Common Shares · 177,576 shares Expires 2036-01-13 F2 · derivative.exercise_date: The options will vest 1/3 on January 9, 2027 and the remainder to vest in equal installments quarterly thereafter. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:20 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantCommon Shares | 190,549 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000037 · form4.xml · nonDerivative · entry 1 McFadden Michael E. · CIK 0001748333 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,549 F1 · shares: Restricted stock units that vest on 1/3 on January 9, 2027, 1/3 on January 9, 2028 and 1/3 on January 9, 2029. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 17:40 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantCommon Share Options · Derivative | 496,947 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0000912282-25-000199 · form4.xml · derivative · entry 1 McFadden Michael E. · CIK 0001748333 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 496,947 Underlying: Common Shares · 496,947 shares Expires 2035-02-25 F1 · derivative.exercise_date: The options will vest over 36 months, with 12.5% vesting on the grant date and remainder to vest 8% per quarter thereafter and 7.5% vesting on the final quarter. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 16:23 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | PurchaseCommon Shares | 2,608 | $5.75 | $14,996.00 |
DisclosureSEC source: 0000912282-24-000811 · form4.xml · nonDerivative · entry 1 McFadden Michael E. · CIK 0001748333 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · by The Michael and Sherri McFadden Family Trust Disclosed balance after: 14,142 Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 17:24 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-19-000779 · doc4.xml · derivative · entry 1 McFadden Michael E. · CIK 0001748333 · CCO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2029-01-06 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 18:08 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 4,750 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001209191-18-055412 · doc4.xml · derivative · entry 1 McFadden Michael E. · CIK 0001748333 · CCO of Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Shares · 4,750 shares Expires 2028-10-14 F1 · derivative.exercise_date: 25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.